Related Experiment Videos
Membranes for therapeutic apheresis.
Shuhei Nakaji1, Tsuneatsu Yamamoto
1Medical Products Development Department, Kuraray Co., Ltd., Kurashiki, Japan.
Summary
Double filtration plasmapheresis (DFPP) offers a cost-effective therapy using specialized membranes. The Evaflux 5A plasma fractionator effectively removes LDL, proving beneficial for hyperlipidemia treatment.
Area of Science:
- Biomedical Engineering
- Medical Devices
- Therapeutic Apheresis
Background:
- Kuraray has pioneered various apheresis devices, including plasma separators and fractionators.
- Apheresis membranes, particularly for double filtration plasmapheresis (DFPP), are crucial in therapeutic procedures.
Purpose of the Study:
- To introduce apheresis membranes, focusing on DFPP and its associated plasma fractionators.
- To highlight the clinical and economic advantages of DFPP in treating diverse diseases.
Main Methods:
- Discussion of various plasma separators and the importance of selecting appropriate pore sizes.
- Introduction of the Evaflux 5A ethylene-vinyl alcohol copolymer plasma fractionator for lipoprotein separation.
Main Results:
- DFPP is presented as a clinically and cost-effective apheresis therapy.
- The Evaflux 5A demonstrates efficient separation of low-density lipoprotein (LDL) from high-density lipoprotein (HDL).
Conclusions:
- DFPP is a widely applicable apheresis therapy for various conditions.
- DFPP utilizing the Evaflux 5A is an effective treatment for familial hyperlipidemia.